Physician profile
Karan S Nejad
NPI 1083757744
$3,261.71
in general payments reported to CMS, 2019-2025
26 companies · $440 in 2025
The $440 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $79.73 · 2021: $386 · 2022: $203 · 2023: $534 · 2024: $763 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $338.27 | 2019-2023 | Xarelto |
| Abbott Laboratories | $291.44 | 2019-2024 | |
| Boston Scientific Corporation | $283.34 | 2019-2025 | Watchman Flx |
| Shockwave Medical, INC | $263.73 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $231.34 | 2019-2024 | Farxiga |
| Cvrx, INC. | $222.79 | 2024-2025 | Barostim Neo System |
| Amgen INC. | $199.71 | 2020-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $186.34 | 2019-2024 | |
| Ancora Heart, INC. | $164.00 | 2019 | |
| Silk Road Medical, INC. | $141.12 | 2019 | |
| Pfizer INC. | $134.33 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $128.70 | 2021-2025 | Verquvo |
| Bridgebio Pharma, INC. | $122.20 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $99.22 | 2022-2025 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.96 | 2019-2024 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $86.35 | 2022-2023 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.49 | 2021-2023 | Lifevest |
| Amarin Pharma, INC. | $51.74 | 2019-2021 | |
| Esperion Therapeutics, INC. | $32.27 | 2025 | Nexletol |
| Abiomed | $28.62 | 2024 | Impella |
| Novo Nordisk INC | $22.66 | 2025 | Wegovy |
| Irhythm Technologies, INC. | $18.22 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $16.89 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $13.94 | 2019 | |
| G Medical Diagnostic Services, INC. | $12.13 | 2022 | |
| Heartflow, INC. | $8.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Nejad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.